Skip to main content
. 2003 Nov 17;198(10):1609–1619. doi: 10.1084/jem.20030357

Figure 6.

Figure 6.

Blocking the Fas/FasL interaction in vivo rescues isotype-switched B cells in μMT mice. A neutralizing recombinant FasIg protein was purified and engineered into slow releasing PLGA microcapsules. The microcapsules were administered to μMT mice by intramuscular injection of 10 mg/mouse every 10 d for 8 wk. Mice were first injected at 2 wk of age. Control μMT mice were injected with empty microcapsules. 10 d after the last injection, mice were killed. (A) Serum samples from the mice were assayed for the presence of IgG by ELISA. Results are mean ± SEM of three mice in each group. (B) Detection of γH chain in serum samples by Western blotting. Normal serum sample dilution is 1:10. Samples of μMT mice (control and FasIg-treated) were not diluted. Purified IgG was used as control. Line indicates where irrelevant lane was removed digitally. (C) Quantitation of IgG-producing cells in spleens of μMT mice treated with FasIg relative to μMT and normal mice by ELISPOT. Representative ELISPOT membranes and the calculated frequency of IgG-producing cells per 107 spleen cells are shown. Results are mean ± SEM of three mice in each group. (D) FACS® analysis for κ and IgG expression. Spleen cells from the treated mice were stained for CD19, B220, κ, and IgG. Analysis for κ and IgG expression was performed on 10,000 gated CD19+/B220+ cells. The results shown are representative of eight injected mice in three different experiments.